LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces the acceptance for publication of data confirming analytical performance of the Company's blood-based LungLB® test in the journal BMC Pulmonary Medicine. Springer Nature's BMC Pulmonary Medicine is a globally recognised peer-reviewed medical journal with articles covering all aspects of the prevention, diagnosis and management of pulmonary and associated disorders. The […]
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, is pleased to announce that our two abstract submissions to the Association for Molecular Pathology1 (AMP) have beenaccepted for both presentation at their flagship 2024 Annual Meeting & Expo in Vancouver, BC, Canada from November 19-23rd, and also for publication in the […]
LungLife AI licensure/accreditation information posted here.